Ever since last summer, when Lynn Gemmell’s dog, Bela, was inducted into the trial of a drug that has been shown to significantly lengthen the lives of laboratory mice, she has been the object of intense scrutiny among dog park regulars.
To those who insist that Bela, 8, has turned back into a puppy — “Look how fast she’s getting that ball!” — Ms. Gemmell has tried to turn a deaf ear. Bela, a Border collie-Australian shepherd mix, may have been given a placebo, for one thing.
The drug, rapamycin, which improved heart health and appeared to delay the onset of some diseases in older mice, may not work the same magic in dogs, for another. There is also a chance it could do more harm than good. “This is just to look for side effects, in dogs,” Ms. Gemmell told Bela’s many well-wishers.
Technically that is true. But the trial also represents a new frontier in testing a proposition for improving human health: Rather than only seeking treatments for the individual maladies that come with age, we might do better to target the biology that underlies aging itself.
While the diseases that now kill most people in developed nations — heart disease, stroke, Alzheimer’s, diabetes, cancer — have different immediate causes, age is the major risk factor for all of them. That means that even treatment breakthroughs in these areas, no matter how vital to individuals, would yield on average four or five more years of life, epidemiologists say, and some of them likely shadowed by illness.
A drug that slows aging, the logic goes, might instead serve to delay the onset of several major diseases at once. A handful of drugs tested by federally funded laboratories in recent years appear to extend the healthy lives of mice, with rapamycin and its derivatives, approved by the Food and Drug Administration for organ transplant patients and to treat some types of cancer, so far proving the most effective. In a 2014 study by the drug company Novartis, the drug appeared to bolster the immune system in older patients. And the early results in aging dogs suggest that rapamycin is helping them, too, said Matt Kaeberlein, a biology of aging researcher at the University of Washington who is running the study with a colleague, Daniel Promislow.
But scientists who champion the study of aging’s basic biology — they call it “geroscience” — say their field has received short shrift from the biomedical establishment. And it was not lost on the University of Washington researchers that exposing dog lovers to the idea that aging could be delayed might generate popular support in addition to new data.
“Many of us in the biology of aging field feel like it is underfunded relative to the potential impact on human health this could have,” said Dr. Kaeberlein, who helped pay for the study with funds he received from the university for turning down a competing job offer. “If the average pet owner sees there’s a way to significantly delay aging in their pet, maybe it will begin to impact policy decisions.”
The Latest on: Geroscience
via Google News
The Latest on: Geroscience
- Current State Of Longevity Clinical Trialson September 20, 2019 at 1:05 pm
They are considered to be next generation because this space of research and development integrates numerous scientific and technical subdomains such as geroscience, artificial intelligence, and ...
- International conference series on geroscience launched in Shenzhen, Chinaon July 18, 2019 at 1:26 pm
July 18, 2019 (New York, NY) - The first in a series of international meetings bringing together researchers from around the world to advance the revolutionary approach to healthy aging known as ...
- Israel fast becoming world hub of aging industryon April 30, 2019 at 9:12 pm
The open-access report cites no fewer than 60 “longevity influencers” (mainly researchers in the field of geroscience), 10 R&D centers, 10 non-profit organizations, 10 annual conferences, 160 ...
- OU College of Medicine receives $10.7 million grant for geroscience researchon February 9, 2019 at 4:00 pm
OKLAHOMA CITY - To advance research in the field of geroscience - which studies the relationship between aging and disease - the University of Oklahoma College of Medicine has been awarded a $10.7 ...
- China to boost geroscience researchon December 15, 2018 at 6:01 pm
China will boost its geroscience research and develop more geroscience-related academic disciplines to respond to its ageing population, according to a symposium Saturday. The country will explore the ...
- China to boost geroscience researchon December 15, 2018 at 12:09 pm
BEIJING, Dec. 15 (Xinhua) -- China will boost its geroscience research and develop more geroscience-related academic disciplines to respond to its ageing population, according to a symposium Saturday.
- global-longevity-science-landscape-2017-geroscience-companieson February 13, 2018 at 4:00 pm
Singularity University, Singularity Hub, Singularity Summit, SU Labs, Singularity Labs, Exponential Medicine, Exponential Finance and all associated logos and design elements are trademarks and/or ...
- Measuring Longer, Healthier Lives: News in Geroscienceon August 4, 2017 at 12:26 pm
Dr. Austad was among the global experts exploring the difference between longevity and a healthy lifespan, or healthspan, at this month’s Disease Drivers of Aging: 2016 Advances in Geroscience Summit ...
- Researchers working to advance aging researchon August 17, 2016 at 6:50 am
"The Geroscience Network is a collaborative way to overcome barriers and move us closer to our shared goal of increasing healthspan -- the healthy, independent years of life for the elderly." Mayo ...
- Geroscience: Research strategy supports GSIG's efforts to integrate aging into chronic disease researchon November 5, 2014 at 4:00 pm
Scientists who have been successful in delaying mammalian aging with genetic, dietary and pharmacological approaches have developed a research strategy to expand Geroscience research directed at ...
via Bing News